Highlander Silver Corp. (HLSCF)

CTI BioPharma Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Dec 31, 2020
Net Income	-4.38	-2.12	-5.55	-0.72	-1.79	-0.32
Depreciation & Amortization	0.24	0.27	4.62	0.01	0.23	0.01
Asset Writedown & Restructuring Costs	0.09	0.09	-	-	-	-
Stock-Based Compensation	1.13	0.63	0.24	0.4	-	-
Provision & Write-off of Bad Debts	0.26	0.09	0.08	-	-	-
Other Operating Activities	-0.22	-0.34	-0.04	-	0.9	0.09
Change in Accounts Receivable	-0.06	-0.09	-0.04	-	-	-
Change in Accounts Payable	0.16	0.03	0.08	0.1	0.06	0.07
Change in Other Net Operating Assets	0	-0.01	0.01	-0.03	-0.01	-0
Operating Cash Flow	-2.91	-1.46	-0.62	-0.24	-0.6	-0.15
Capital Expenditures	-0.03	-0.03	-	-0	-	-1
Sale of Property, Plant & Equipment	0.14	0.01	-	-	-	-
Cash Acquisitions	-7.05	-7.05	-	-	3.38	-
Other Investing Activities	-1.14	-1.21	-1.29	-1.04	-0.51	-
Investing Cash Flow	-8.08	-8.29	-1.29	-1.04	2.87	-1
Issuance of Common Stock	39.38	12.24	-	0.01	-	2.18
Other Financing Activities	-0.04	-0.04	-	-	-	-0.01
Financing Cash Flow	39.34	12.19	-	0.01	-	2.17
Foreign Exchange Rate Adjustments	-0.04	-0.17	0.16	-0.26	0.04	0
Net Cash Flow	28.31	2.27	-1.74	-1.53	2.32	1.01
Free Cash Flow	-2.94	-1.49	-0.62	-0.25	-0.6	-1.16
Free Cash Flow Per Share	-0.04	-0.02	-0.02	-0.01	-0.03	-0.09
Levered Free Cash Flow	0.81	1.09	1.39	-0	-	-1.33
Unlevered Free Cash Flow	0.9	1.09	1.39	-0	-	-1.33
Change in Net Working Capital	-2.21	-1.53	0.01	-0.19	-	0.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.